PTC Therapeutics vice president reports insider sale

Vice President Mark Elliott Boulding reported selling 2,073 PTC Therapeutics shares at $64.06 in a Form 4 filing. The filing also showed a same-day exercise of 2,073 shares at $39.42 under a 10b5-1 plan.